ライフサイエンスコーパス: HCV antibody

1 NA was detected an average of 31 days before HCV antibody.

2 HIV-1-positive women who tested negative for HCV antibody.

3 with significantly different efficiency with HCV antibodies.

4 investigation who were seropositive for anti-HCV antibodies.

5 ved between viremia and the presence of anti-HCV antibodies.

6 ides mimicking this structure to elicit anti-HCV antibodies.

7 care workers tested negative for HCV RNA and HCV antibodies.

8 creases the efficacy of broadly neutralizing HCV antibodies.

9 differed by age (50 vs. 42 years), positive HCV antibody (11 vs. 2%) and death from stroke (51 vs. 4

10 Of 2514 women, 97 (3.9%) had anti-HCV antibodies, 54 (2.1%) were viremic and of those, 52

11 nts transplanted during 1996 to 2001 who had HCV antibodies (Ab) measured before transplantation.

12 screened for HCV and 64 (6%) had a positive HCV antibody (Ab) result at initial screening.

13 ibe early experience with integrated opt-out HCV antibody (Ab) screening of medically stable baby boo

14 through the HCV continuum of care (CoC) from HCV antibody (Ab) screening, HCV-RNA confirmation, engag

15 screening with liver function tests (LFTs), HCV antibody (Ab) screening, or HCV RNA screening in var

16 The testing pathway includes HCV antibody (Ab), automatic HCV RNA for Ab-positive pat

17 prevalence of IDU, HIV antibody, HBsAg, and HCV antibody among PWID were selected and, where multipl

18 induced by DNA immunization to generate anti-HCV antibodies and anticore CTLs.

19 sion could be specifically inhibited by anti-HCV antibodies and by at least one peptide.

20 n at Cairo University were screened for anti-HCV antibodies and HCV RNA, and viremic women were teste

21 with HCV-infected siblings were screened for HCV antibodies and HCV RNA.

22 ents had HCV RNA (chronic infection), 91 had HCV antibodies and no HCV RNA (cleared infection), and 1

23 At a minimum, HCV antibody and alanine aminotransferase testing should

24 in women with or without HIV-1 infection, by HCV antibody and HCV RNA status.

25 women were grouped on the basis of positive HCV antibody and HCV RNA tests.

26 rom injection drug users (IDUs) persistently HCV antibody and RNA negative despite high-risk behavior

27 positive but RNA negative, and 112 who were HCV antibody and RNA positive.

28 f a mathematical model and based on maternal HCV antibody and viremia.

29 s among women who tested positive for HIV-1, HCV antibody, and HCV RNA, compared with HIV-1-positive

30 lood samples were tested for the presence of HCV antibodies (anti-HCV), HBV surface antigen (HBsAg),

31 er, Women and Infants Transmission Study had HCV antibody (anti-HCV by second-generation ELISA) and H

32 urveys had data on diabetes status and serum HCV antibody (anti-HCV) or HCV RNA.

33 rs, Chembio, OraSure, and MedMira, submitted HCV antibody (anti-HCV) rapid screening assays to the CD

34 se Control and Prevention in 1998 recommends HCV antibody (anti-HCV) testing for persons with specifi

35 y assigned to receive a one-time offering of HCV antibody (anti-HCV) testing via one of three indepen

36 ase, we identified all subjects initiated on HCV antibody (anti-HCV) therapy from 2001 to 2014, and a

37 ed with incident HCV in MSM since 1984, 5310 HCV antibody (anti-HCV)-negative MSM in the Multicenter

38 2-1993, the prevalence of hepatitis C virus (HCV) antibodies (anti-HCV) among US blood donors was 0.3

39 t EIA were 97.78, 93.54, and 97.66% for anti-HCV antibodies, anti-HBsAg antibodies, and HBsAg, respec

40 Thus, we have designed an HCV antibody assay that employs a conformational protein

41 Seronegative participants were tested for HCV antibodies at baseline, at 6 months, and at 12 month

42 erase (ALT) elevations and seroconversion to HCV antibodies at week 10 p.i.

43 nreliable, with two patients having negative HCV antibody but a positive HCV RNA at diagnosis.

44 strates the principle that neutralizing anti-HCV antibodies can be induced by epitope-based, engineer

45 viruses, likely due to synergy between anti-HCV antibodies derived from different plasma donors, and

46 bitory activity of broadly neutralizing anti-HCV antibodies elicited by candidate vaccines.

47 (3) were significantly associated with lower HCV antibody end-point titers.

48 t hepatitis B surface antigen in three (6%), HCV antibody (enzyme-linked immunosorbent assay II suppl

49 Prevalence of hepatitis C virus (HCV) antibody has been reported in Mexican Americans, bu

50 A blood sample was screened for HCV antibody (HCV AB) using the OraQuick HCV Rapid Antib

51 C virus (HCV) viremia, involving testing for HCV antibody (HCVAb) followed by a nucleic acid test (NA

52 (RVF) immunotechnology for detection of anti-HCV antibodies in an effort to extend the capabilities o

53 ised 7,005 and 21,729 persons diagnosed with HCV antibodies in Denmark and Scotland, respectively.

54 Enzyme immunoassay detection of anti-HCV antibodies in specimens from DBS was reliable after

55 alence was estimated by the presence of anti-HCV antibodies incorporating respondent-driven sampling

56 These results suggest that profiling anti-HCV antibody is useful for monitoring HCV therapy, espec

57 IV infection on B cell function, we compared HCV antibody levels and specificities in 29 HCV-infected

58 HCV antibody levels were unreliable, with two patients h

59 ds that simultaneously estimated the time to HCV-antibody loss in uninfected infants and the diagnost

60 The patient was HCV antibody negative and HCV RNA negative by PCR of the

61 There were 148 women who were HCV antibody negative, 34 who were HCV antibody positive

62 Twenty-eight percent were HCV antibody negative/RNA positive at the time of acute

63 50% of uninfected children became HCV-antibody negative by 8 months and 95% by 13 months.

64 HCV-antibody negative recipients of HCV-antibody positiv

65 ic blood donors from 1991 to 2002 and 10,259 HCV antibody-negative (HCV-) donors matched for year of

66 lanted from HCV antibody-positive (HCV+) vs. HCV antibody-negative donors.

67 with a history of illicit drug use who were HCV antibody-negative in 1988 were followed semiannually

68 None of the 233 HCV antibody-negative patients were shown to be viremic

69 HCV RNA was detected in 38% of HCV antibody-negative subjects by the whole-blood-based

70 n (HCV RNA-positive) and 1,941 HCV-negative (HCV antibody-negative) controls.

71 /HTLV-II(+), and HIV(-)/HTLV-II(-)), 376 had HCV antibodies, of whom 305 had detectable HCV load.

72 We performed both G2 and G3 EIAs for anti-HCV antibodies on 1,134 serum samples collected during t

73 Blood donors who tested positive for HCV antibodies on enzyme immunoassay were classified acc

74 V infection assessed by the presence of anti-HCV antibodies or HCV RNA.

75 00 IU/L were followed up within 12 months by HCV antibody or RNA testing.

76 ated with screening for HCV infection (using HCV antibody or RNA), performed temporal analyses to ass

77 ia whose HLA-identical donor was found to be HCV antibody positive and HCV RNA positive by polymerase

78 who were HCV antibody negative, 34 who were HCV antibody positive but RNA negative, and 112 who were

79 egative recipients who received kidneys from HCV antibody positive donors (D-HCV) (n=48); and (3) HCV

80 ups of adult renal allograft recipients: (1) HCV antibody positive recipients (R-HCV) (n=32); (2) HCV

81 In the 5777 people who were HCV antibody positive, 2086 (34.4%) reported harmful or

82 f the 5777 people who inject drugs that were HCV antibody positive, 440 (5.5%) were aware of their st

83 Of 4713 patients, 652 (13.8%) were HCV antibody positive.

84 nty-six of the 1000 (7.6%) participants were HCV antibody positive; none were confirmed by detection

85 HCV-antibody negative recipients of HCV-antibody positive hearts were identified from Januar

86 infection in heart transplant recipients of HCV-antibody positive organs is not known.

87 At baseline, 521 patients (45.4%) were HCV-antibody positive, 85 (7.4%) were hepatitis B surfac

88 D are living with HIV, 52.3% (42.4-62.1) are HCV-antibody positive, and 9.0% (5.1-13.2) are HBV surfa

89 tes between those who were transplanted from HCV antibody-positive (HCV+) vs. HCV antibody-negative d

90 ,259 recombinant immunoblot assay-confirmed, HCV antibody-positive (HCV+), allogeneic blood donors fr

91 We studied HCV antibody-positive adults with HIV in the EuroSIDA st

92 The prevalence of HCV antibody-positive and chronic HCV infection at acces

93 isk of vertical HCV infection to children of HCV antibody-positive and RNA-positive women was 5.8% (9

94 of risk were generated for children born to HCV antibody-positive and viremic women, aged >/=18 mont

95 Participants who were HCV antibody-positive at enrolment and those with HCV an

96 een eradicated or persists at a low level in HCV antibody-positive HCV RNA-negative individuals.

97 HCV antibody-positive individuals were 3-fold more likel

98 Of 155 singleton infants born to HCV antibody-positive mothers, 13 (8.4%) were HCV infect

99 iver transplant recipients transplanted with HCV antibody-positive organs.

100 We analyzed 36 liver samples from HCV antibody-positive patients (30 from patients with ch

101 HCV RNA was detected in 85% of HCV antibody-positive patients by the whole-blood method

102 Conclusion: Nonviremic HCV antibody-positive patients have a liver biopsy that

103 Sixty-two percent of respondents would refer HCV antibody-positive patients with abnormal transaminas

104 approach to the management of 2 hypothetical HCV antibody-positive patients, 1 with elevated and the

105 HCV-specific CD4+ T-helper-cell response in HCV antibody-positive persons who lack detectable plasma

106 eliability of G2 and G3 EIAs to confirm anti-HCV antibody-positive results.

107 The five HCV antibody-positive subjects who were negative by whol

108 with a history of injection drug use and an HCV antibody-positive test result during follow-up.

109 One hundred seventy-two HCV antibody-positive, serum HCV RNA-negative patients u

110 an age of 56 +/- 11 SD) received hearts from HCV-antibody-positive donors.

111 All reports of anti-HCV antibody prevalence were much higher than any single

112 702 IDUs aged 18-30 years were screened for HCV antibodies; prevalence was 27%.

113 est that HCV infection could cause some anti-HCV-antibody-producing hybridoma B cells to make less-pr

114 stern blot analyses with anti-c-Myc and anti-HCV antibodies provided positive identification of both

115 Patients who screened HCV antibody reactive between 1 May and 31 October 2014

116 Of the 532 HCV antibody-reactive patients, 435 completed viral load

117 ection, and screening identified 532 (14.4%) HCV antibody-reactive patients.

118 ent of respondents would retest patients for HCV antibody, regardless of risk factors and transaminas

119 ne the effect of HIV coinfection on the anti-HCV antibody response, we measured anti-HCV envelope bin

120 ends in HCV RNA testing following a positive HCV antibody result among persons in 4 large healthcare

121 rus (HCV) infection requires both a positive HCV antibody screen and confirmatory nucleic acid testin

122 cted to full clinical evaluation, ELISA anti-HCV antibodies screening, parasitological examination fo

123 between 2000 and 2011, 14 534 (85%) received HCV antibody screening within 3 months of enrolling in c

124 ntibody-positive at enrolment and those with HCV antibody seroconversion during follow-up (1996 to 20

125 atabase of 13,664 MHD patients who underwent HCV antibody serology testing at least once during a 3-y

126 Subjects were identified from 1,454 HCV antibody-seropositive US veterans tested for HCV RNA

127 o three genotype 1a-derived HCV antigens and HCV antibody serotype were examined in chronically HCV i

128 nd HCV infection was assessed via a positive HCV antibody test and a positive HCV RNA test.

129 Screening with the HCV antibody test followed by the nucleic acid test for

130 s than two-thirds of persons with a positive HCV antibody test had a follow-up RNA test.

131 ements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were no

132 ements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were no

133 e adjusted risk ratio (aRR) for receiving an HCV antibody test, and costs were estimated using activi

134 th having an RNA test after a first positive HCV antibody test.

135 for HCV RNA with the use of a more sensitive HCV-antibody test).

136 Therefore, we suggest that the HCV antibody testing algorithm for the VITROS assay migh

137 sly undiagnosed HCV disease, as suggested by HCV antibody testing and HCV polymerase chain reaction a

138 months), saliva was collected for anonymous HCV antibody testing and risk behavior data were obtaine

139 Anti-HCV antibody testing was performed for 4582, or 90%, of

140 HCV antibody testing was performed on excess samples.

141 solicitation), evaluated hepatitis C virus (HCV) antibody testing, diagnosis, and costs for each of

142 HCV antibody tests were performed by the enzyme-linked i

143 This antigen elicited anti-HCV antibodies that targeted conserved neutralizing epit

144 The pre-HIV infection HCV antibody titer was a predictor of the subsequent tit

145 he combined anti-core, anti-E1, and anti-NS4 HCV antibody titers in those with SVRs but not in those

146 A decline of hepatitis C virus (HCV) antibody titers (anti-HCV), ultimately resulting in

147 HCV antibody was detected in 128 of 924 (14%; 95% confid

148 ce with either gradual or rapid loss of anti-HCV antibody was observed in four animals within 5 month

149 characterized by persistent HCV RNA and anti-HCV antibody was observed in two animals.

150 Age-standardized prevalence of HCV antibody was similar in NHANES 2007-2010 (1.5%) and

151 sing fasting glucose and medical history and HCV antibodies were assessed at baseline.

152 Using the HCV-LP ELISA, high-titer anti-HCV antibodies were detected in individuals infected wit

153 HCV antibodies were found in 12.1% of 207 syringes teste

154 egative for human immunodeficiency virus and HCV antibodies were recruited into a prospective study i

155 IDUs <30 years old who tested negative for HCV antibody were enrolled in a prospective cohort.

156 t the proportion of patients with a positive HCV antibody who had a positive HCV RNA was 0.5 (95% con

157 Approximately 2% of U.S. adults have HCV antibodies, with the majority having chronic infecti

158 Fully implemented birth cohort screening for HCV antibody would have missed 36 of 128 (28%) of cases